Study advances cancer-killing cream for melanoma

October 10, 2012

(Medical Xpress)—RMIT University researchers have designed a peptide that imitates a melanoma-killing virus, in a biomedical engineering advance that could lead to the development of a cream to target and treat Australia's "national cancer".

The RMIT team has successfully synthesised a peptide that mimics the activity of a virus protein, with showing the peptide kills while leaving normal unharmed.

Lead investigator Dr Taghrid Istivan said peptide therapy had the potential to lead to new, non-invasive treatments for melanoma, which is responsible for 75 per cent of deaths in Australia.

"Australia has the highest incidence of melanoma in the world, with more than 11,000 new diagnoses each year," Dr Istivan said.

"Currently the only effective treatment for early stage melanoma is surgery to cut out the tumour and healthy skin surrounding the affected mole.

"The peptide we have developed is toxic to melanoma cells but leaves normal skin cells unaffected.

"With further work, including clinical trials, we hope our research could lead to the development of a cream to painlessly and efficiently treat early stage melanoma."

Dr Istivan and her colleagues in RMIT's Health Innovations Research Institute and the School of Applied Sciences tested the efficacy of a peptide - a short chain of - that was designed to work like the proteins of the myxoma virus, a cancer-killing virus shown to be toxic to melanoma in previous studies.

"A is big, expensive to synthesise and has inherent risks when used in medical treatments, because all viruses can mutate," she said.

"By synthesising a small peptide that mimics the action of a protein, we can offer a stable, safe, targeted and cost-effective alternative."

The researchers used a novel bioengineering method developed at RMIT by Professor Irena Cosic and Dr Elena Pirogova, from the School of Electrical and Computer Engineering, to design the peptide. The peptide was synthesised as a powder, liquefied and tested in vitro on normal human cells and cells.

Dr Istivan is presenting the research findings at the 40th Congress of the International Society of Oncology and Biomarkers (13 - 17 October, Jerusalem).

Explore further: Potential new treatment target identified for melanoma skin cancer

Related Stories

Potential new treatment target identified for melanoma skin cancer

August 15, 2012
New research from Western University, Canada, has identified a potential new target for the treatment of melanoma, the deadliest of all skin cancers. Silvia Penuela and Dale Laird discovered a new channel-forming protein ...

RNA spurs melanoma development

May 10, 2011
Traditionally, RNA was mostly known as the messenger molecule that carries protein-making instructions from a cell's nucleus to the cytoplasm. But scientists now estimate that approximately 97 percent of human RNA doesn't ...

Scientists find molecule in immune system that could help treat dangerous skin cancer

July 8, 2012
Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.